Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Core Insights - Oculis Holding AG announced the winner of the Ramin Tadayoni Award 2025, recognizing contributions in retinal research [1][2] - The award honors Dr. Prithvi Ramtohul for his significant work in retinal imaging and diseases [3][4] - Oculis is committed to advancing retinal research and honoring the legacy of Professor Ramin Tadayoni [4] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs [6] - The company has a late-stage clinical pipeline that includes three core product candidates: OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease [6] - Oculis is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team [6]